Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 3;6(4):e12736.
doi: 10.1002/rth2.12736. eCollection 2022 May.

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

Javier Trujillo-Santos  1 , Dominique Farge-Bancel  2 , José María Pedrajas  3 , Covadonga Gómez-Cuervo  4 , Aitor Ballaz  5 , Andrei Braester  6 , Isabelle Mahé  7 , Aurora Villalobos  8 , José Antonio Porras  9 , Manuel Monreal  10 ; RIETE Investigators
Collaborators, Affiliations

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

Javier Trujillo-Santos et al. Res Pract Thromb Haemost. .

Abstract

Background: Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death.

Objectives: The objective of the RIETECAT study was to compare the long-term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondary prevention of VTE in adults with active cancer.

Methods: We used the data from the multicenter, multinational RIETE registry to compare the rates of VTE recurrences, major bleeding, or death over 6 months in patients with active cancer and acute VTE using full doses of enoxaparin versus dalteparin or tinzaparin, and a multivariable Cox proportional hazard model was used to analyze the primary end point.

Results: From January 2009 to June 2018, 4451 patients with active cancer received full doses of the study drugs: enoxaparin, 3526 patients; and dalteparin or tinzaparin, 925 (754 + 171) patients. There was limited difference in VTE recurrences (2.0% vs 2.5%) and mortality rate (19% vs 17%) between the enoxaparin and dalteparin or tinzaparin subgroups. However, there was a slight numerical increase in major bleeding (3.1% vs 1.9%). Propensity score matching confirmed that there were no differences in the risk for VTE recurrences (adjusted hazard ratio [aHR], 0.81; 95% confidence interval [CI], 0.48-1.38), major bleeding (aHR, 1.40; 95% CI, 0.80-2.46), or death (aHR, 1.07; 95% CI, 0.88-1.30) between subgroups.

Conclusions: In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.

Keywords: LMWH; cancer; cohort; dalteparin; enoxaparin; recurrences; tinzaparin; venous thromboembolism.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Flowchart of patients. DVT, deep vein thrombosis; LMWH, low‐molecular‐weight heparin; PE, pulmonary embolism; VTE, venous thromboembolism
See this image and copyright information in PMC

References

    1. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125:490‐493. - PMC - PubMed
    1. Monreal M, Falga C, Valdes M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006;4:1950‐1956. - PubMed
    1. Trujillo‐Santos J, Nieto J, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE registry. Thromb Haemost. 2008;100:435‐439. - PubMed
    1. Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population‐based cohort study. Blood. 2014;123:3972‐3978. - PMC - PubMed
    1. Farge D, Trujillo‐Santos J, Debourdeau P, et al. Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore). 2015;94(32):e1235. - PMC - PubMed